Inventor · disambiguated record
Erich Koller
Also filed as: KOLLER ERICH
10 granted patents·24 pending applications·166 citations·filing 1996–2025
88Inventor score
Files withISIS PHARMACEUTICALS INC10HOFFMANN LA ROCHE6BENNETT C F4IONIS PHARMACEUTICALS INC2ROCHE INNOVATION CT COPENHAGEN AS2
Top patents by PatentIndex Score
34 records- 0197US7199107B2Antisense modulation of kinesin-like 1 expressionISIS PHARMACEUTICALS INC·Filed 2003·Granted Apr 3, 2007·128 cites·45 claims
- 0285US7718628B2Antisense modulation of kinesin-like 1 expressionISIS PHARMACEUTICALS INC·Filed 2006·Granted May 18, 2010·4 cites·19 claims
- 0381US8865884B2Antisense modulation of kinesin-like 1 expressionISIS PHARMACEUTICALS INC·Filed 2013·Granted Oct 21, 2014·1 cites·17 claims
- 0481US8470795B2Antisense modulation of kinesin-like 1 expressionDOBIE KENNETH W·Filed 2010·Granted Jun 25, 2013·2 cites·54 claims
- 0581US7163927B2Antisense modulation of kinesin-like 1 expressionISIS PHARMACEUTICALS INC·Filed 2002·Granted Jan 16, 2007·11 cites·19 claims
- 0674US7375212B2Modulation of Aurora B expressionISIS PHARMACEUTICALS INC·Filed 2005·Granted May 20, 2008·1 cites·10 claims
- 0770US2024182898A1ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSIONHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0868US11898145B2Enhanced oligonucleotides for inhibiting RTEL1 expressionHOFFMANN LA ROCHE·Filed 2022·Granted Feb 13, 2024·0 cites·17 claims
- 0967US8999951B2Compounds and methods for improving cellular uptake of oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2012·Granted Apr 7, 2015·0 cites·19 claims
- 1067US2024336920A1Threose nucleic acid antisense oligonucleotides and methods thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1162US8318496B2Compounds and methods for improving cellular uptake of oligomeric compoundsKOLLER ERICH·Filed 2008·Granted Nov 27, 2012·0 cites·10 claims
- 1261US2005096292A1Notch1 inhibitors for inducing apoptosisFiled 2004·Application pending·0 cites
- 1361US2005227938A1Antisense modulation of TFAP2C expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 1459US5576676ABase plate module for an electromagnetic switching device specifically of a contactorALLEN BRADLEY CO·Filed 1996·Granted Nov 19, 1996·19 cites·8 claims
- 1559US2024167040A1Antisense oligonucleotideHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1656US2005267063A1Antisense modulation of p70 S6 kinase expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 1756US2003158144A1Antisense modulation of estrogen receptor beta expressionFiled 2003·Application pending·0 cites
- 1856US2003225019A1Notch1 inhibitors for inducing apoptosisFiled 2003·Application pending·0 cites
- 1955US2015322428A1Compounds and methods for improved cellular uptake of antisense compoundsISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2053US2018002695A1Compounds and methods for improved cellular uptake of antisense compoundsIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2149US2022031730A1Enhanced oligonucleotides for modulating fubp1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2248US2004110150A1Modulation of Ephrin-B2 expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 2347US2003050270A1Antisense modulation of Inhibitor-kappa B Kinase-beta expressionFiled 2002·Application pending·0 cites
- 2447US2003224513A1Antisense modulation of Notch1 expressionISIS PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 2546US2015315580A1Compounds and methods for improving cellular uptake of oligomeric compoundsISIS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2645US2025376684A1Threose nucleic acid antisense oligonucleotides and methods thereofHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2745US2005215504A1Antisense modulation of sterol regulatory element-binding protein-1 expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 2844US2003125272A1Antisense modulation of toll-like receptor 4 expressionFiled 2001·Application pending·0 cites
- 2944US2003203862A1Antisense modulation of MDM2 expressionFiled 2001·Application pending·0 cites
- 3041US2006154885A1Modulation of SLC26A2 expressionBENNETT C F·Filed 2005·Application pending·0 cites
- 3140US2021221837A1Oligonucleotides comprising a phosphorotrithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3239US2017283804A1Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3338US2021292358A1Oligonucleotides comprising a phosphorotrithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3437US2003185829A1Jagged 2 inhibitors for inducing apoptosisFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →